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Abstract
Background. Glioblastoma ranks among the most lethal cancers, with current therapies offering only pal-
liation. Paracrine vascular endothelial growth factor (VEGF) signaling has been targeted using anti-angiogenic 
agents, whereas autocrine VEGF/VEGF receptor 2 (VEGFR2) signaling is poorly understood. Bevacizumab resist-
ance of VEGFR2-expressing glioblastoma cells prompted interrogation of autocrine VEGF-C/VEGFR2 signaling in 
glioblastoma.
Methods. Autocrine VEGF-C/VEGFR2 signaling was functionally investigated using RNA interference and exog-
enous ligands in patient-derived xenograft lines and primary glioblastoma cell cultures in vitro and in vivo. VEGF-C 
expression and interaction with VEGFR2 in a matched pre- and post-bevacizumab treatment cohort were analyzed 
by immunohistochemistry and proximity ligation assay.
Results. VEGF-C was expressed by patient-derived xenograft glioblastoma lines, primary cells, and matched surgi-
cal specimens before and after bevacizumab treatment. VEGF-C activated autocrine VEGFR2 signaling to promote 
cell survival, whereas targeting VEGF-C expression reprogrammed cellular transcription to attenuate survival and 
cell cycle progression. Supporting potential translational significance, targeting VEGF-C impaired tumor growth in 
vivo, with superiority to bevacizumab treatment.
Conclusions. Our results demonstrate VEGF-C serves as both a paracrine and an autocrine pro-survival cytokine in 
glioblastoma, promoting tumor cell survival and tumorigenesis. VEGF-C permits sustained VEGFR2 activation and 
tumor growth, where its inhibition appears superior to bevacizumab therapy in improving tumor control.
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Glioblastoma ranks among the most lethal primary central 
nervous system tumors, with median survival of less than 
15 months.1,2 Robust vascularization, often associated with 
the overexpression of vascular endothelial growth factor 
A (VEGF-A), is a hallmark of glioblastoma.3 The VEGF recep-
tor 2 (VEGFR2) is a primary effector of VEGF-A signaling, 
expressed by both endothelial and tumor cells to stimulate 
paracrine and autocrine effects of VEGF signaling. Although 
VEGF-A/VEGFR2 signaling is most commonly associated 
with regulation of endothelial cells, autocrine VEGFR2 acti-
vation also promotes proliferation and self-renewal of glio-
blastoma stemlike cells.4–8 The collective pro-tumorigenic 
effects of VEGF signaling have led to the development of 
targeted therapeutics against VEGF-A/VEGFR2.9 Despite 
initial enthusiasm from preclinical and clinical studies, 
targeting VEGF-A using a humanized anti-VEGF antibody, 
bevacizumab (Avastin), failed to show improvement in 
overall survival for glioblastoma patients.10,11 Bevacizumab 
remains FDA approved for glioblastoma and continues to 
be widely used, despite the lack of survival benefit, sup-
porting the importance of understanding treatment fail-
ure with bevacizumab. Glioblastoma evades bevacizumab 
through multiple mechanisms, revealing the complexity of 
pro-angiogenic signaling.12 These mechanisms, together 
with the lack of inhibitory effect of bevacizumab on tumor 
cells expressing VEGF-A/VEGFR2, suggest alternative 
ligand-mediated activation of VEGFR2 upon bevacizumab 
treatment.4,8,13
The VEGF ligand family comprises several ligands, 
including VEGF-C and VEGF-D, with overexpression associ-
ated with disease progression in various solid tumors.14–17 
However, the roles of these ligands in glioblastoma is 
poorly defined. VEGF-C, a main driver of lymphatic ves-
sel formation, serves critical roles during embryogenesis, 
tumorigenesis, and metastasis.18,19 VEGF-C undergoes 
extensive proteolytic processing, whereupon mature 
VEGF-C binds VEGFR3 and VEGFR2 primarily located on 
lymphatic and vascular endothelial cells, respectively.20 
VEGF-C and its cognate receptors are expressed on tumor 
cells, including leukemic, skin, and gastric cells, facilitating 
tumor progression in part through autocrine signaling.21–23 
In glioblastoma, VEGF-C is expressed by endothelial cells, 
tumor cells, and infiltrating macrophages.24–27 In contrast 
to VEGF-D, VEGF-C is overexpressed in glioblastoma com-
pared with nonneoplastic brain,24–26,28 and high VEGF-C 
levels have been documented to inform poor progno-
sis.26–28 While most previous studies focused on the prog-
nostic significance of VEGF-C and its role in endothelial 
stimulation,28,29 functional studies interrogating the role 
of VEGF-C signaling in glioblastoma tumor cells are still 
missing.
In the present study, we investigated the role of auto-
crine VEGF-C/VEGFR2 signaling in glioblastoma. We dem-
onstrate that VEGF-C expressed by glioblastoma cells 
mediates their survival and cell cycle progression and pro-
motes tumorigenicity, potentially contributing to bevaci-
zumab resistance.
Methods
Cell Culture
Patient-derived glioblastoma xenograft lines CPH017 
(p4), CPH036 (p6), CPH047 (p3m1), CPH048 (p6), and pri-
mary cell cultures (see Supplementary Table  S1) were 
derived in the Hamerlik lab30; 1966 was provided by J. N. 
Rich (University of California San Diego)4; and IN326 and 
IN1123 were provided by I. Nakano (University of Alabama 
at Birmingham).31,32 Human dermal microvascular endo-
thelial cells, human dermal lymphatic endothelial cells 
(HDLECs), and brain microvascular endothelial cells were 
purchased from Lonza, PromoCell, and 3H Biomedical, 
respectively. For cell culture conditions, see the 
Supplementary materials.
Inhibitors, Growth Factors, and Blocking 
Antibodies
We purchased SU1498 (Millipore), bevacizumab (Avastin, 
25 mg/mL, Roche), recombinant VEGF-A-165aa (50 µg/mL, 
Miltenyi Biotec), and recombinant human mature VEGF-C 
(Thr103-Arg227~21 kDa; 10 µg/mL, R&D Systems).
SiRNA Transfection/shRNA Transduction
Cells were transfected using 75 pmol of either VEGF-C–
small interfering (si)RNA (siVEGF-C-1: esiRNA pool/
Importance of the study
VEGF ligands stimulate tumor angiogenesis through 
effects on both endothelial cells and tumor cells, 
prompting the development of anti-angiogenic target-
ing strategies, including bevacizumab, which blocks 
VEGF-A ligand binding to VEGFR2. Unfortunately, bev-
acizumab generates only transient responses for glio-
blastoma patients with universal treatment failure in 
the long term. One potential mechanism of treatment 
failure could derive from compensatory expression of 
other VEGF ligands in glioblastoma cells with associ-
ated autocrine signaling through VEGFR2. Here, we 
demonstrate that the VEGF-C ligand maintains VEGFR2 
activation in glioblastoma cells despite bevacizumab 
treatment. In patient-derived tumor specimens and 
cultures, VEGF-C was expressed and activated VEGFR2, 
unaffected by bevacizumab treatment. Targeting 
VEGF-C led to transcriptional reprogramming, inhib-
iting glioblastoma cell survival, cell cycle, and tumor-
initiating capacity. Collectively, these results support 
autocrine VEGF-C/VEGFR2 signaling as important in 
glioblastoma growth and a potential mechanism to 
evade bevacizumab.
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EHU013781, Sigma-Aldrich; siVEGF-C-2: single siRNA/
HSS111277, ThermoFisher Scientific) or scrambled con-
trol siRNA (siCtrl: Stealth RNAi Negative Control Duplex 
Med CG, ThermoFisher Scientific). Lentiviral transduc-
tion was used for delivery of VEGF-C–short hairpin (sh)
RNA (shVEGF-C-A: TRCN0000425238, shVEGF-C-B: 
TRCN000058507, Sigma-Aldrich) or nontargeting control 
shRNA (shCtrl: SHC007, Sigma Aldrich). For details, see the 
Supplementary materials.
Patient Surgical Biopsy Specimens
Paired formalin-fixed paraffin-embedded (FFPE) samples 
(n  =  12 pathologically confirmed glioblastoma) collected 
pre- and postprogression on bevacizumab in combin-
ation with CPT-11 (irinotecan) were previously described.33 
Moreover, blood-plasma samples were collected at time 
of surgical resection for glioblastoma of 7 other patients. 
Patient material was used according to the Declaration 
of Helsinki and Danish legislation under permission 
from the Danish Data Protection Agency (2006-41-6979) 
and the scientific ethical committee for Copenhagen and 
Frederiksberg (H-3-2009-136, H-2-2012-069).
Western Blot
Western blot (WB) analysis was performed as described 
previously.34 Semi-quantification of band intensities was 
performed using ImageJ software. Antibodies are listed in 
the Supplementary materials.
Quantitative Real-Time PCR
RNA was purified using the QIAshredder/RNeasy Mini kit 
(Qiagen). Synthesis of cDNA and quantitative real-time 
(qRT)-PCR reactions were performed using the Superscript 
III Platinum qRT-PCR kit with SYBR Green (ThermoFisher 
Scientific). Quantification of gene expression levels was 
done according to the comparative cycle threshold method 
and normalized to expression of reference human genes 
TOP1, EIF4A2, and CYC1. Primer sequences are listed in the 
Supplementary materials.
Cell Viability Assay
We plated 0.7–2 × 104 cells/well in 96-well plates. Viability 
was measured using MTT assay (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl-tetrazolium bromide) as previously 
described.34
Enzyme-Linked Immunosorbent Assay
Cells were plated at 1.25  ×  106 cells/mL. Conditioned 
media were collected 48–72 hours later and subjected to 
Human VEGF-Quantikine enzyme-linked immunosorbent 
assay (ELISA) or Human VEGF-C-Quantikine ELISA (R&D 
Systems), following manufacturer’s instructions using a 
Synergy2 microplate reader (BioTek).
Proximity Ligation Assay 
VEGF-C and VEGFR2 colocalization was analyzed using 
the Duolink In Situ Red Starter Kit Mouse/Rabbit (Sigma-
Aldrich). Detailed method description can be found in the 
Supplementary materials.
Immunohistochemistry 
Four-micrometer sections were deparaffinized, hydrated, 
blocked for endogenous peroxidase using H2O2, and pre-
treated in a microwave oven with a Tris/ethylene glycol tetra-
acetic acid buffer (pH 9.0) before immunostaining. Staining 
was conducted on a Dako Cytomation autostainer using 
antibody for VEGF-C (Supplementary materials). Staining 
was evaluated using an Olympus BX51 microscope.
Gene Expression Analysis
Gene expression analysis was performed using the 
HumanGene 2.0 ST GeneChip array (Affymetrix), and dif-
ferential expression analysis was conducted with P-value 
threshold of 0.05 and Bonferroni–Hochberg correction. 
Gene set enrichment analysis (GSEA) was performed by 
analyzing gene sets (with applied set size filters: min = 15, 
max = 500) from the Reactome pathway database. Detailed 
analysis description is found in the Supplementary 
materials.
Cell Cycle Analysis
Analysis of cell cycle profiles and mitotic index was done 
as previously described32,34 (see Supplementary materi-
als), using the FACSVerse Cell Sorter (BD Biosciences) and 
FlowJo software.
In Vivo Tumor Formation
Intracranial glioblastoma xenografts were established 
by orthotopic injection of 50 000–100 000 viable cells 
(transfected with siVEGF-C/siCtrl or transduced with 
shVEGF-C/shCtrl) in 8- to 10-week-old Naval Medical 
Research Institute nude female mice (Taconic) as previ-
ously described.35 Selected mice were treated intraperi-
toneally with bevacizumab (5 mg/kg) or immunoglobulin 
(Ig)G every second day for 2 weeks from day 2 post cell 
injection. Mice were humanely euthanized when present-
ing neurological signs and/or 20% weight loss. Animal 
care and all experimental procedures were performed 
under the approval of the Danish Animal Welfare Council 
(2012-15-2934-00267/2012-15-2934-00636).
Statistical Analysis
Quantified in vitro data are presented as mean  ±  SD, ± 
SEM, or ± 95% CI, as indicated. For all in vitro experiments, 
n indicates the number of independent performed experi-
ments, while for the in vivo data it represents the number 
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of animals used. Statistical analysis was performed using 
GraphPad Prism (v7.02).
Results
VEGF-C Activated VEGFR2 in Bevacizumab-
Treated Glioblastoma Cells
We previously demonstrated that glioblastoma cells 
express VEGFR2, stimulating tumor growth.4 To evaluate 
VEGFR2 expression in primary patient-derived glioblast-
oma models, we performed qRT-PCR and WB analysis. 
Human microvascular endothelial cells (HMVECs) and 
human brain microvascular endothelial cells (HBMECs) 
served as positive controls. VEGFR2 expression was het-
erogeneous, ranging from negative (CPH036, CPH047, 
CPH048) to moderate (IN326 and IN1123) to high (CPH017 
and 1966). VEGFR2 levels in the high-expressing glio-
blastoma cultures were comparable to levels of HMVECs 
and HBMECs (Fig.  1A and B). Quantitative RT-PCR ana-
lysis confirmed VEGFA expression in all tested cultures 
with HMVECs as controls (Fig. 1B). We selected represen-
tative VEGFR2high (CPH017 and 1966)  and VEGFR2moderate 
(IN1123) glioblastoma cells to interrogate the functionality 
of autocrine VEGFR2 signaling. Cells were treated with the 
exogenous VEGF-A165 ligand and/or the VEGFR2 tyrosine 
kinase inhibitor SU1498. CPH017, IN1123, and 1966 cells 
showed significant sensitivity to 10 µM SU1498 (Fig. 1C), 
whereas this concentration had no effect on VEGFR2negative 
CPH036 cells (Supplementary Figure S1). Pretreatment of 
CPH017 cells with SU1498 decreased VEGFR2 phosphor-
ylation upon stimulation with VEGF-A165 (Fig.  1D and E), 
confirming the functionality of VEGFR2 in tumor cells. In 
contrast, although bevacizumab treatment of glioblastoma 
cells sequestered secreted VEGF-A, no significant impair-
ment of glioblastoma cell viability was observed (Fig. 1F 
and G; Supplementary Figure  S1). WB analysis of cells 
treated with bevacizumab indicated increased expression 
and activation of VEGFR2 (Fig. 1H). Collectively, these data 
demonstrate that tumor cell VEGFR2 remains activated in 
the absence of VEGF-A, suggesting that other VEGF ligands 
may stimulate VEGFR2 in the absence of VEGF-A.
To determine the potential role of alternative VEGF 
ligands, we interrogated our patient-derived models for 
VEGF-C expression. As shown in Fig. 2A, 5 of 7 glioblast-
oma cultures expressed VEGF-C at levels comparable to 
control HDLECs, which were previously demonstrated to 
express both VEGF-C and VEGFR3.36 While VEGF-C expres-
sion in most cultures correlated with VEGFR2 expression, 
VEGFR3 was detected in only 2 cell cultures at very low lev-
els (Fig. 2A). Bevacizumab treatment (0.5 mg/mL) did not 
alter VEGF-C secretion in 1966 cells and induced expres-
sion in CPH017 and IN1123 glioblastoma cells (Fig.  2B), 
supporting VEGF-C activation of VEGFR2 activation in the 
absence of VEGF-A. To rule out VEGF-C secretion as a cell 
culture artifact, we compared VEGF-C levels in matched 
collected plasma samples from a glioblastoma patient 
with conditioned media collected from in vitro primary cell 
cultures derived from the same patient (n = 7; Fig. 2C and 
Supplementary Table S1). A significant positive correlation 
indicated that findings for VEGF-C from in vitro cultures are 
representative of patient tumors.
VEGF-C Interacts with VEGFR2 In Vitro and 
Ex Vivo
To verify that VEGF-C binds to VEGFR2 in glioblastoma 
cells, we performed a proximity ligation assay (PLA), 
which confirmed VEGF-C/VEGFR2 interaction. PLA spots, 
denoting interaction, were localized to both plasma 
membrane and cytosol (Fig.  2D, E and Supplementary 
Figure  S2). VEGF-C and VEGFR2 colocalization was con-
firmed in FFPE glioblastoma surgical biopsy specimens 
collected pre and post bevacizumab treatment. The cohort 
(Supplementary Table S2) consisted of 12 pairs of parallel 
tumor samples from surgery before treatment with com-
bined bevacizumab and irinotecan chemotherapy (Pre-Bev 
samples) and after treatment relapse (Post-Bev samples). 
Immunohistochemistry showed heterogeneous granu-
lar VEGF-C expression pattern in tumor cells, endothelial 
cells of both neoplastic and nonneoplastic vessels, and 
tumor-infiltrating microglia and macrophages (Fig.  3B, C 
and Supplementary Figure S3). Although heterogeneous, 
VEGF-C expression was found in all patient samples, and 
no systematic changes in VEGF-C expression were associ-
ated with bevacizumab treatment. PLA performed on FFPE 
specimens (6 selected patients of our cohort) confirmed 
the interaction between VEGF-C and VEGFR2 in samples 
collected before and after bevacizumab treatment (Fig. 2D 
and Supplementary Figure S4).
VEGF-C Signaling Regulates Glioblastoma Cell 
Survival
Our previous studies demonstrated that activation of 
VEGFR2 mediated by VEGF-A triggers Akt/extracellular 
signal-regulated kinase (ERK)/phospholipase C (PLC)‒
gamma signaling in glioblastoma cells.37 Therefore, we 
measured the activation of these signaling pathways in 
response to exogenous VEGF-C. In gain-of-function stud-
ies, VEGF-C treatment induced activation of VEGFR2/
PLC-gamma/ERK1/2 signaling in glioblastoma cells, in 
both the presence (Fig.  4A) and the absence of VEGF-A 
(Supplementary Figure  S5A). To determine loss-of-
function modulation of VEGF-C, we performed siRNA-
mediated knockdown of VEGF-C using a nontargeting 
control siRNA (siCtrl) or 2 independent siRNAs against 
VEGF-C (siVEGF-C-1, siVEGF-C-2) in glioblastoma cells. 
Effective knockdown was validated by qRT-PCR and WB 
(Fig. 4B and C). VEGF-C loss led to reduced cell viability 
(Fig.  4F) and induced apoptosis (cleavage of caspase-3; 
Fig. 4G). In addition, we observed increased protein lev-
els of signal transducer and activator of transcription 1 
and interferon regulatory factor 1, mediators of interferon 
signaling with anti-proliferative effects in cancer follow-
ing VEGF-C knockdown (Supplementary Figure S5B).38,39 
Concordant with a potential adaptive role, VEGF-C knock-
down resulted in increased VEGF-A secretion as assessed 
by qRT-PCR and ELISA (Fig.  4D and E; Supplementary 
Figure  S6D). The differential regulation of VEGF-A and 
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Fig. 1 VEGFR2 tyrosine kinase expressed by glioblastoma cells remains active under bevacizumab therapy. (A) Western blot (WB) for VEGFR2 and 
tubulin in a panel of patient-derived glioblastoma cultures. (B) Quantitative RT-PCR analysis of VEGF-A and VEGFR2 expression in glioblastoma 
cells standardized to expression in human microvascular endothelial cells (HMVECs). Data are presented as mean ± SD, n = 3. The y-axis is log10 
transformed. (C) Viability of CPH017, IN1123, and 1966 cells treated with SU1498 (10 µM) or left unstimulated. Data are presented as mean ± SD, n 
= 3. Significance determined by 2-way ANOVA with Bonferroni post-test. (D) Representative WB of total and phosphorylated VEGFR2 and tubu-
lin in CPH017 cells plated overnight in Neurobasal media without epidermal growth factor and basic fibroblast growth factor, then treated with 
either SU1498 (30 µM for 3 h), VEGF-A (40 ng/mL, 15 min), or the combination (30 µM SU1498 for 3 h followed by 40 ng/mL VEGF-A for 15 min). (E) 
Quantification of relative phosphorylated-VEGFR2/tubulin levels from WB analysis. Data are presented as mean ± SD, n = 3. Significance deter-
mined by one-way ANOVA with Dunnett’s post-test correction and ratio paired 2-sample t-test. (F) Viability of glioblastoma cells treated 7 days with 
bevacizumab (Bev) (0–2 mg/mL). Data are presented as mean ± SD, n = 3. Significance determined by 2-way ANOVA with Bonferroni post-test cor-
rection. (G) ELISA quantification of VEGF-A secretion by glioblastoma cells treated with Bev (0.5 mg/mL, 48 h) or IgG control. Data are presented as 
mean ± SD, n = 3. N.D. denotes that signal could not be detected. (H) Representative WB of total and phosphorylated VEGFR2 or tubulin in CPH017 
and 1966 cells treated for 72 h with Bev (0.5 mg/mL) or IgG. *P ≤ 0.05; **P ≤ 0.01; ****P ≤ 0.0001; NS: nonsignificant.
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VEGF-C ligands prompted us to evaluate the combinato-
rial effect of VEGF-C knockdown and bevacizumab treat-
ment, which reduced viability compared with VEGF-C 
knockdown alone, indicating additional proliferative 
effects of VEGF-C (Fig. 4H). In validation studies, transduc-
tion of glioblastoma cells with stable shRNA-mediated 
VEGF-C knockdown led to decreased PLC-gamma/ERK1/2 
signaling and viability (Supplementary Figure S6).
VEGF-C Knockdown Impairs Cell Cycle 
Progression of Glioblastoma Cells
To better delineate autocrine signaling and identify the 
biological role of VEGF-C in glioblastoma cells, we inter-
rogated gene expression changes in CPH017 cells follow-
ing VEGF-C knockdown using Affymetrix GeneChip Human 
Gene 2.0 ST arrays. A  total of 222 genes with absolute 
log2-fold change in expression above 2 (log2fc ≥ 2) were 
found to be significantly altered (P  ≤  0.05). Ninety-eight 
genes were downregulated and 124 genes upregulated 
(Fig.  5A; Supplementary Tables  S3 and S4). Gene set 
enrichment analysis showed significant downregulation 
of pathways regulating the cell cycle, DNA replication, and 
mitosis (Fig.  4B and Supplementary Figure  S7). Cyclin-
family members, cell-division cycle regulators, and his-
tone coding genes scored among the top downregulated 
candidates (Supplementary Table  S3). Interferon/cytokine 
signaling associated with immunomodulatory responses 
ranked among the top upregulated GSEA pathways fol-
lowing VEGF-C knockdown (Fig.  5B and Supplementary 
Figure S8).
To examine the effects of VEGF-C knockdown on the cell 
cycle, we performed a flow cytometry–based cell cycle 
analysis, including incorporation of EdU (5-ethynyl-2'-de-
oxyuridine; ethynyl-labeled (deoxy)uridine) to mark S 
phase cells and staining for phosphorylated histone 3Ser10 
(p-H3Ser10) to mark mitotic cells. VEGF-C loss induced the 
apoptotic sub-G1 population from 2.4% for siCtrl to 4.8 and 
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Fig. 2 VEGF-C is expressed under bevacizumab therapy and interacts with VEGFR2 in glioblastoma cells. (A) Quantitative RT-PCR analysis 
of VEGF-C and VEGFR3 expression in glioblastoma cells standardized to HDLECs. Data represented as mean ± SD; n =  2. The y-axis is 
log10 transformed. N.D. = not detected. (B) ELISA quantification of VEGF-C secretion by glioblastoma cells treated 72 h with bevacizumab (Bev; 
0.5 mg/mL) or IgG. Data represented as mean ± SEM; n = 3. Significance determined by paired 2-sample t-test. *P ≤ 0.05. (C) Correlation of 
VEGF-C ELISA quantification in matched samples of blood-plasma and conditioned media (72 h) from tumor-derived cell cultures of 7 glioblas-
toma patients. Significance was determined by Spearman’s correlation analysis. (D) Representative confocal images showing PLA signal (red), 
F-actin (gray), and 4′,6′-diamidino-2-phenylindole (blue) of glioblastoma cells. Staining with only VEGF-C antibody (AB) was used as a negative 
control. (E) Quantification of PLA dots in glioblastoma cells. Data are represented as mean ± SEM; n > 40 cells.
D
ow
nloaded from
 https://academ
ic.oup.com
/neuro-oncology/article-abstract/20/11/1462/5043488 by R
oyal Library C
openhagen U
niversity user on 16 April 2019
 1468 Michaelsen et al. VEGF-C promotes glioblastoma resistance to bevacizumab
4.3% for siVEGF-C-1 and siVEGF-C-2, respectively (Fig. 5C 
and D). The proliferative index, calculated as percentage of 
EdU-positive cells, decreased from 15% (siCtrl cells) to 1% 
(siVEGF-C-1) and 3% (siVEGF-C-2), respectively. The mitotic 
index, calculated as percentage of p-H3Ser10–positive 
cells, decreased from 1.45% (siCtrl) to 0.39% and 0.36% for 
siVEGF-C-1 and siVEGF-C-2, respectively (Fig. 5D). WB anal-
ysis confirmed reduced retinoblastoma hyperphosphoryl-
ation and cyclin E2/B1/A2 levels, supporting impaired G1-S 
phase transition in siVEGF-C cells (Fig.  5F). VEGF-C loss 
increased ataxia telangiectasia mutated and gamma-H2AX 
phosphorylation, indicating DNA damage accumulation, a 
prerequisite for cell cycle arrest (Fig. 5G).
Targeting of VEGF-C Reduces In Vivo 
Glioblastoma Tumor Growth
To assess the contribution of VEGF-C signaling to glioblas-
toma tumor growth, we performed in vivo survival stud-
ies using both siRNA and shRNA approaches validated in 
vitro, as noted above. VEGF-C knockdown extended the 
survival of immunocompromised mice bearing orthotopic 
Fig. 3 VEGF-C expression and interaction with VEGFR2 in glioblastoma cells is sustained upon bevacizumab therapy. (A) Immunohistochemical 
evaluation of VEGF-C in matched pre- and post-bevacizumab glioblastoma patient surgical biopsy specimens. Quantification of staining intensity 
and frequency in tumor cells, macrophages, and endothelial cells in each tumor sample is displayed. Statistical significance is determined by 
2-sample t-test. NS: nonsignificant. (B) Representative images of 2 of 12 patients analyzed by VEGF-C immunohistochemistry. Scale bar, 50 μm. 
(C) Confocal images of PLA signal (red), F-actin (green), and 4′,6′-diamidino-2-phenylindole (blue) in FFPE pre- and post-bevacizumab patient 
glioblastoma specimens. Representative images with PLA spot quantification from tumor samples of 2 out of 6 analyzed patients are shown.
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Fig. 4. VEGF-C regulates canonical VEGFR2 survival signaling. (A) WB analysis of downstream VEGFR2 signaling in CPH017 glioblastoma cells 
starved for 24 h followed by stimulation with VEGF-A (40 ng/mL) or VEGF-C (0.2 µg/mL). (B) Quantitative RT-PCR analysis of VEGF-C expression 
in glioblastoma cells 48 h following transfection with either siCtrl (nontargeting control) or siVEGF-C (VEGF-C targeting siRNA). Data are repre-
sented as mean ± SEM; n = 3 or 4. Significance determined with 1-sample t-tests setting the hypothetical value to 1. (C) WB for VEGF-C and tubu-
lin in CPH017 cells 72 h following siCtrl or siVEGF-C transfection. (D) Quantitative RT-PCR analysis of VEGF-A expression in CPH017 and IN1123 
cells 48 h following siCtrl or siVEGF-C transfection. Data are represented as mean ± SEM; n = 3 or 4. Significance determined with 1-sample 
t-tests setting the hypothetical value to 1. (E) ELISA quantification of VEGF-A in conditioned media from CPH017 glioblastoma cells transfected 
with siCtrl or siVEGF-C. Data are represented as mean ± SEM; n = 2. Significance determined by 1-way ANOVA with Dunnett’s post-test correc-
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Significance determined by 2-way ANOVA with Bonferroni post-test correction. (G) WB of pro- and cleaved (Cl.) caspase-3 and tubulin in CPH017 
and IN1123 glioblastoma cells 72 h following siCtrl or siVEGF-C transfection. (H) Viability of CPH017 and IN1123 glioblastoma cells 5 days after 
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= 3. Significance determined by 1-way ANOVA with Dunnett’s post-test correction. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
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Fig. 5 VEGF-C loss leads to transcriptional changes and cell cycle arrest in glioblastoma cells. (A) Heat map of significantly differentially 
expressed genes (log2fc ≥ 2 and adjusted P ≤ 0.05) 48 h after VEGF-C knockdown compared with siCtrl. (B) GSEA using a 479-gene set from the 
Reactome pathway database. Top 10 most significant downregulated and 10 most upregulated gene sets are shown with normalized enrichment 
score (NES). (C) Representative fluorescence activated cell sorting (FACS) plot showing cell cycle profile of CPH017 cells post transfection with 
siCtrl or siVEGF-C. (D) Quantification of sub-G1, G1, S, and G2/M cell cycle populations–based FACS analysis. Data are displayed as mean ± SEM; 
n = 3–4. The y-axis is log10 transformed. Statistical significance was determined by one-way ANOVA. *P ≤ 0.05; **P ≤ 0.01; ****P ≤ 0.0001; NS: 
nonsignificant. (E) Mitotic index (%) of CPH017 cells 72 h post siCtrl and siVEGF-C transduction. (F) WB analysis of phosphorylated and total 
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(G) WB for DNA damage markers phosphorylated and total ataxia telangiectasia mutated and gamma-H2AX in glioblastoma cells 72 h following 
shCtrl or shVEGF-C transduction.
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xenografts of either CPH017 or IN1123 glioblastoma cells 
(Fig. 6). VEGF-C knockdown augmented survival more than 
did bevacizumab treatment (Fig.  6B). Although VEGF-C 
knockdown and bevacizumab treatment had combinatorial 
benefit in vitro, no additional benefit was detected in xeno-
graft studies.
Discussion
Few options are available for glioblastoma patients suf-
fering tumor recurrence or progression. Given the role 
of microvascular proliferation as a histologic hallmark 
of glioblastoma and detection of VEGF in glioblastoma 
surgical specimens, angiogenesis has been a prominent 
area of research in neuro-oncology. Bevacizumab treat-
ment leads to a high response rate in early treatment, but 
tumor control is transient and no consistent impact on 
patient survival has been found.10,11 Despite the lack of sur-
vival benefit, bevacizumab was approved by the FDA and 
remains in wide use for tumor recurrence and treatment 
of radiation-induced necrosis. The molecular underpin-
nings for evasion of anti–VEGF-A therapy remain an area of 
active investigation.12,40
Our results demonstrate for the first time that auto-
crine VEGF-C/VEGFR2 signaling regulates glioblastoma 
cell viability, cell cycle, and in vivo tumor growth, under-
scoring the global requirement for VEGF signaling in glio-
blastoma. Despite VEGF-A sequestration by bevacizumab, 
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Fig. 6 VEGF-C loss promotes DNA damage, reduces survival marker expression, and impairs in vivo glioblastoma growth. (A) Kaplan–Meier 
survival analysis of mice bearing orthotopically transplanted viable CPH017 glioblastoma cells transduced with either VEGF-C–siRNA or Ctrl–
siRNA. Significance was determined by log-rank analysis; *P ≤ 0.05, **P ≤ 0.01, NS: nonsignificant. (B) Kaplan–Meier survival analysis of mice 
bearing orthotopically transplanted viable CPH017 glioblastoma cells. Group 1: transduced with shCtrl and treated with IgG control. Group 2: 
treated with bevacizumab alone (10 mg/kg; for details see “Materials and Methods” section). Group 3: transduced with shVEGF-C-A alone. 
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VEGFR2 remains active on glioblastoma cells, suggesting 
an alternative pathway for receptor activation (Fig.  1H). 
Mahfouz and coworkers41 recently reported that bevaci-
zumab induces VEGFR2 expression in gastrointestinal can-
cer. Collectively, our results support an important role of 
VEGF-C for glioblastoma growth, suggesting a novel anti-
angiogenesis evasion mechanism, where glioblastoma 
cells secrete VEGF-C in response to bevacizumab treat-
ment, facilitating sustained VEGFR2-mediated pro-survival 
signaling, tumor cell proliferation, and cell cycle progres-
sion (Fig.  6C). Quantitative RT-PCR and ELISA analyses 
confirmed VEGF-C expression in our collection of xeno-
graft lines and primary glioblastoma cells. Model lines 
chosen for this study coexpressed VEGFR2 and VEGF-C 
but lacked or expressed very low VEGFR3 levels, indicat-
ing that VEGF-C may operate via VEGFR2 (Figures  1A, B 
and 2A). VEGF-C/VEGFR2 interacted in vitro and ex vivo 
with concordance between the VEGF-C protein levels and 
VEGF-C/VEGFR2 interaction (Figures  2C, D and 3B–D). 
VEGF-C expression and its interaction with VEGFR2 were 
sustained in glioblastomas after bevacizumab treatment 
(Fig.  3B–D and Supplementary Figure  S3). Glioblastoma 
surgical specimens and patient-derived cultures display 
variable VEGF-C expression (Figures  2B and 3B, C), sug-
gesting that targeting VEGF-C will require precise selection 
of patients. Intratumoral and intertumoral heterogeneity 
of VEGF-C expression may be driven by cellular environ-
mental factors, like hypoxia, which induces VEGF-C expres-
sion in metastatic cancer cells.42 VEGF-C protein levels 
correlated with matched patient plasma samples and 
conditioned media collected from corresponding primary 
cultures (Fig.  3A), supporting patient-derived cultures 
as an accurate model to test VEGF-C biology in glio-
blastoma. Immunohistochemistry confirmed previously 
reported VEGF-C expression by tumor-infiltrating mac-
rophages and other nontumor cell types (Supplementary 
Figure  S3),25,43,44 suggesting that glioblastoma cells with 
low VEGF-C expression could be exposed to substantial 
amounts of VEGF-C ligand in vivo from other cell types.
Signaling downstream from VEGF-C includes canon-
ical VEGFR2 signaling via PLC-gamma and ERK (Fig.  4A, 
Supplementary Figures  S5 and S6). VEGFR1/2 signaling 
positively correlated with ERK activation,8 which is con-
cordant with our data, where VEGF-C stimulation induced 
ERK activation in glioblastoma cells (Fig.  4A). Further, 
VEGF-C stimulated tumor viability and cell cycle progres-
sion (Figures 4–6 and Supplementary Figure S6), concord-
ant with previous studies on autocrine VEGF-C signaling in 
other cancers.17
Bevacizumab treatment did not affect glioblastoma 
cell survival in vitro (Fig.  1F), with minimal change or 
increased secretion of VEGF-C in glioblastoma cultures 
after bevacizumab treatment (Fig.  2B). VEGF-A secretion 
was consistently increased after siRNA-mediated knock-
down of VEGF-C (Fig.  4E). The mechanism(s) by which 
VEGF-C stimulates the expression of VEGF-A is not clear, 
but an increase in VEGF-C mRNA levels following beva-
cizumab therapy was previously demonstrated in glio-
blastoma and endothelial cells.29 Reciprocally, Zhao and 
coworkers27 reported VEGF-A induction of VEGF-C in ret-
inal epithelial cells. As ERKs are ubiquitous intracellular 
signaling mediators of innumerous cellular functions, 
dysregulation of ERK, possibly in with PLC-gamma, may 
contribute to VEGF-A/VEGF-C compensatory expression in 
glioblastoma. Existence of this compensatory mechanism 
points to a global requirement for a VEGF signaling route 
in glioblastoma maintenance, yet the increase in VEGF-A 
levels did not compensate for the anti-proliferative and 
anti-tumorigenic effect of VEGF-C knockdown, suggest-
ing non-overlapping effects of VEGF ligands. Combined 
VEGF-A (bevacizumab) and VEGF-C (siRNA) targeting in 
glioblastoma cells (Fig. 4H) was only modestly superior at 
reducing cell viability in comparison to inhibiting VEGF-C 
alone in vitro and had no added benefit in vivo, poten-
tially due to dependency of the VEGF ligands on corecep-
tors, such as neuropilin-1 and -2,45 for VEGFR2 activation, 
thereby making coreceptor availability a key element in 
the impact of VEGF-A and VEGF-C ligand binding on down-
stream signaling.
In conclusion, we demonstrate that VEGF-C/VEGFR2 
signaling promotes glioblastoma cell viability, cell cycle 
progression, and tumor growth in part through autocrine 
signaling. As VEGF-C expression and VEGF-C/VEGFR2 inter-
action remained stable under bevacizumab treatment, 
autocrine VEGF-C signaling may represent a novel escape 
mechanism employed by glioblastomas to counteract bev-
acizumab therapy.
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